Point72 Middle East FZE’s Pacira BioSciences PCRX Stock Holding History

Point72 Middle East FZE’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-23,613	Closed	-$724K	–	1788
2023 Q3	$724K	Buy	23,613 +6,629	+39%	+$239K	0.02%	680
2023 Q2	$681K	Buy	+16,984	New	+$702K	0.02%	696
2023 Q1	–	Sell	-11,622	Closed	-$449K	–	2059
2022 Q4	$449K	Buy	+11,622	New	+$565K	0.02%	773

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Point72 Middle East FZE's PCRX Position: Q4 2023 in Review

Point72 Middle East FZE sold out of Pacira BioSciences (PCRX) in Q4 2023, closing a stake of 23,613 shares — an estimated $724K sold.

Point72 Middle East FZE first reported a position in PCRX in Q4 2022 and held it in 3 quarters. The position peaked at $724K in Q3 2023. 261 funds tracked by Wall St. Rank hold PCRX as of Q4 2023.

Point72 Middle East FZE reported no remaining Pacira BioSciences position as of Q4 2023 after selling out during the quarter.
Point72 Middle East FZE sold 23,613 Pacira BioSciences shares in Q4 2023, an estimated $724K.
Point72 Middle East FZE first reported a position in Pacira BioSciences in Q4 2022 and held it in 3 quarters.
Point72 Middle East FZE's Pacira BioSciences position peaked at $724K in Q3 2023.
261 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2023.

Based on Point72 Middle East FZE's 13F filing for Q4 2023, filed 14 Feb 2024.